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Congenital mirror movements (CMM) are characterized by involuntary movements of one side of the body that mirror intentional
movements on the opposite side. CMM reflect dysfunctions and structural abnormalities of the motor network and are mainly inherited
in an autosomal-dominant fashion. Recently, heterozygous mutations inDCC, the gene encoding the receptor for netrin 1 and involved
in the guidance of developing axons toward the midline, have been identified but CMM are genetically heterogeneous. By combining
genome-wide linkage analysis and exome sequencing, we identified heterozygousmutations introducing premature termination codons
in RAD51 in two families with CMM. RAD51mRNAwas significantly downregulated in individuals with CMM resulting from the degra-
dation of the mutated mRNA by nonsense-mediated decay. RAD51 was specifically present in the developing mouse cortex and, more
particularly, in a subpopulation of corticospinal axons at the pyramidal decussation. The identification of mutations in RAD51, known
for its key role in the repair of DNA double-strand breaks through homologous recombination, in individuals with CMM reveals a totally
unexpected role of RAD51 in neurodevelopment. These findings open a new field of investigation for researchers attempting to unravel
the molecular pathways underlying bimanual motor control in humans.Mirror movements (MM) are involuntary movements of
one side of the body that mirror intentional movements
on the opposite side. Mild MM are physiological in young
children and gradually disappear within the first decade of
life probably because of the maturation of the motor
network.1 Congenital mirror movements (CMM [MIM
157600]) persisting after age 10 in subjects with no other
clinical feature constitute a rare disorder that is mainly in-
herited in an autosomal-dominant fashion although
sporadic cases also exist. MM predominate in the upper
limbs, with muscles controlling the fingers and hands
being constantly involved, and their intensity increases
with the complexity of the voluntary movement. MM
impair the ability to perform tasks requiring skilled
bimanual coordination and are associated with pain in
the upper limbs during sustained manual activities. In
this setting, MM reflect multiple dysfunctions and struc-
tural abnormalities of the motor network, including
altered decussation of the corticospinal tracts.2
Recently, heterozygous mutations in DCC (deleted in
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The Americathe receptor for netrin 1 (NTN1 [MIM 601614]), have
been identified in families with autosomal-dominant
CMM.3,4 Impairment of DCC/netrin 1 signaling, which
promotes attraction and guidance of developing axons
toward the midline, results in alterations of axonal fiber
crossing and abnormal ipsilateral connections.3,4 MM are
genetically heterogeneous, however; no DCC mutations
have been identified in several familial and sporadic
cases.4,5
We have previously ruled outDCCmutations in a French
family (Family A) with autosomal-dominant MM.4Written
informed consent was obtained from all patients before
blood sampling. The study received approval from
ethical standards committee on human experimentation
(INSERM, CHU Pitie´-Salpeˆtrie`re). Genome-wide linkage
analysis with SNP microarrays followed by genotyping
with 92 microsatellite markers on uninformative or posi-
tive regions in this family identified a single linked region
with a maximal multipoint LOD score value (þ2.4) in
chromosome region 15q14-q21.2 (Figure 1A). A common
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Figure 1. Identification of RAD51 Mutations in Two Independent Families
(A) LOD score plot for genome-wide linkage analysis in Family A, revealing a single locus with a maximal multipoint LOD score value on
chromosome arm 15q (Z ¼ þ2.4). Twenty-six family members (7 symptomatic individuals, 3 obligate carriers, 12 at-risk asymptomatic
relatives, and 4 spouses) were genotyped by linkage-24 microarrays (Illumina). Multipoint LOD scores were calculated with Merlin 1.0
(affected-only analysis, autosomal-dominant trait, disease allele frequency of 0.00001, penetrance of 80%, null phenocopy rate). All
regions with LOD scores >2 other than that on chromosome 15 were further analyzed with microsatellite markers and excluded on
the basis of the absence of a common haplotype in all affected family members.
(B) Refinement of the chromosome 15 interval with eight microsatellite markers (D15S1010, D15S102, D15S221, D15S129, D15S514,
D15S659, D15S119, D15S982) showing a common haplotype segregating in all affected family members. Multipoint LOD scores
were recalculated from themicrosatellite markers in the chromosome 15 interval via Allegro 1.0 with the same parameters as those previ-
ously used (Zmax ¼ þ2.7).
(C) Confirmation of the c.760C>T (p.Arg254*) mutation in RAD51 by Sanger sequencing in Family A.
(D) The coding region of RAD51 was amplified with 11 primer pairs (sequences available on request) in the index cases of Families B
(from Germany) and C (from UK). The c.855dupA (p.Pro286Thrfs*37) mutation in RAD51 was identified in Family B (pedigree).and encompassing a 14.4Mb region, segregated in all eight
affected family members and in eight asymptomatic rela-
tives, including three obligate carriers. The multipoint
LOD score, recalculated from microsatellite marker geno-
types and including all eight affected members, reached
þ2.7, its maximal expected value in view of the pedigree
structure (Figure 1B). The region contained 223 known
genes, but only one, SEMA6D (MIM 609295), was poten-
tially involved in neuronal migration. Direct sequencing
of its coding sequence detected no mutations in Family A
or in a second family (from Germany) with two affected
members (Family B). In addition, analysis of the Family A302 The American Journal of Human Genetics 90, 301–307, Februaryproband by high-resolution CGH array (Nimblegen HD-2
microarrays, Roche) revealed no microdeletion or duplica-
tion within the candidate interval.
We then sequenced the entire exome in two affected
members of Family A (individuals 54 and 91). A total of
32,390 and 33,648 variants were identified in each subject
(Table S2 available online). Further analysis focused on the
eight variants (five SNPs and three indels) that were (1)
heterozygous in the two affected subjects, (2) absent
from the dbSNP database (version 132), and (3) contained
in the linked interval (Table 1). Seven variants were
confirmed by Sanger sequencing, four of which were also10, 2012
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The Americafound in control individuals. The three remaining variants
included two intronic substitutions predicted to have no
effect on splicing, and a nonsense mutation (c.760C>T
[p.Arg254*], RefSeq accession number NM_002875) in
exon 8 of RAD51 (MIM 179617). This nonsense mutation
cosegregated with MM in Family A (Figure 1C) and was
absent from 644 healthy unrelated European individuals.
As an alternativemethod to identify themutated gene in
Family A, we searched for deregulated genes in lympho-
blasts from affected subjects. Reverse-transcribed RNA
from lymphoblasts of four affected subjects and three
unaffected noncarrier relatives of Family Awere hybridized
on Illumina HumanHT-12 beadchips. Two independent
statistical analyses restricted to genes contained in the
chromosome 15 interval showed that RAD51 mRNA was
significantly downregulated in affected versus control
individuals (fold difference ¼ 0.7, p ¼ 0.009; Table 2;
Figures 2A–2C). By pretreating the lymphoblastic cells of
affected members of Family A with emetin, we demon-
strated that this downregulation corresponded to the
degradation of the mutated mRNA by nonsense-mediated
decay (Figure 2D). In addition, no truncated protein
could be observed in western blot analysis in untreated
lymphoblastic cells of three affected family members (not
shown).
To confirm that mutations in RAD51 can cause MM,
we screened the RAD51 coding sequence by Sanger
sequencing in the index cases of Family B and of a third
family from the UK in which point mutations in DCC
had been ruled out (Family C). Duplication of an adenine
(c.855dupA), introducing a premature termination codon
(p.Pro286Thrfs*37), was identified in exon 9 of RAD51
in Family B (Figure 1D) and was absent from the 644
control subjects. No mutation was identified in Family C.
Altogether, these results show that heterozygous muta-
tions introducing premature termination codons in
RAD51 cause congenital mirror movements in two unre-
lated families. Because RAD51 mRNA was significantly
downregulated in individuals with CMM of Family A re-
sulting from the degradation of the mutated mRNA by
nonsense-mediated decay, haploinsufficiency is the main
consequence of the mutations and the disease probably
occurs once the amount of functional RAD51 falls below
a critical level.
RAD51 is essential for maintaining genomic integrity
through its involvement in the repair of DNA double-
strand breaks by homologous recombination (HR).6–8
The RAD51 protein interacts with BRCA1 (BRCA1 [MIM
113705]) and BRCA2 (BRCA2 [MIM 600185])9–11 and
defective HR is predicted to contribute to genomic insta-
bility and tumor development. Therefore, mutations in
RAD51 have long been predicted to increase the risk of
developing cancers12 or to modulate the tumor response
or resistance to chemotherapy.13,14 However, a single
constitutional missense variant was reported in two
siblings with breast cancer, indicating that RAD51 is not
a major cancer predisposition gene.15 Our findings aren Journal of Human Genetics 90, 301–307, February 10, 2012 303
Table 2. Classic Class Comparison Analysis of Transcriptomic Data between Affected Individuals and Controls
Unique Illumina ID Gene (MIM Number)
Fold-Change
Controls/Patients
Parametric
p Value
Controls Gene
Expression
Patients Gene
Expression
Expression
in Brain
ILMN_1794157 CATSPER2P1 (-) 1.51 0.002 172.77 114.67 -
ILMN_1697629 PLA2G4B (606088) 1.52 0.005 541.34 356.32 -
ILMN_2363027 RAD51 (179617) 1.42 0.009 200.72 141.79 þ
ILMN_2372379 MGA (-) 1.24 0.009 78.27 63.15 þ
ILMN_2401906 CDAN1 (607465) 1.31 0.014 11358.92 8684.88 þ
ILMN_1710329 MYEF2 (-) 1.96 0.030 23.11 11.8 þ
RNA extracted from lymphoblasts of four affected individuals and three spouses were hybridized on lllumina HumanHT12 beadchips. Expression profiles were
extracted and normalized with Beadstudio software (Illumina). Normalized expression data were log2 transformed. The 131 genes expressed on bead chips
from the 223 candidate genes on chromosome 15 were included for further analysis. Genes differently expressed between affected individuals and controls
were selected for a fold difference of at least 1.2 between groups and a univariate p value of 0.05 with BRB array tools software. Six genes were significantly under-
expressed in the affected individuals compared to the controls (p < 0.05, fold-change > 1.2), four of which were expressed in the brain (expression data provided
by Genecards). No correction for multiple comparisons was used because the number of samples was too small and because this gene list would be intersected
with the second approach (Figure 2A).
Figure 2. Downregulation of RAD51 mRNA in Lymphoblasts from Affected Individuals and Degradation of the Mutated mRNA by
Nonsense-Mediated Decay
In parallel with the whole-exome analysis, we used transcriptomic analysis to identify the gene responsible for MM in Family A, postu-
lating that the mutation might decrease the mRNA expression in lymphoblasts from affected individuals compared to healthy spouses
from the same family. Total RNA extracted from lymphoblasts of four affected individuals and three spouses were hybridized on lllumina
HumanHT12 beadchips. Expression profiles were extracted and normalizedwith Bead studio software (Illumina). Normalized expression
data were log2 transformed. The 131 genes expressed on bead chips from the 223 candidate genes on chromosome 15 were included for
further analysis. Two complementary statistical analyses by two independent investigators were performed to identify genes differen-
tially expressed between the groups. Results of classic class comparison analysis are presented in Table 2.
(A) Gene clustering approach with the pattern discovery tool of GeneATWork software (IBM Research). The filtering criteria for a gene’s
inclusion in a pattern are a maximum deviation of 0.05 and a p value of 0.001. The best patterns classifying the ‘‘phenotype’’ and
‘‘control’’ groups were retained. This approach distinguished the affected individuals from the controls on the basis of four genes under-
expressed in the affected subjects. Among these four genes (CATSPER2P1, CAPN3, RAD51, and PLA2G4B), only two (RAD51 and CAPN3)
were expressed in the brain.
(B) RAD51 was the only gene lying at the intersection of the gene lists obtained with the two statistical analyses.
(C) Expression data obtained for RAD51 on HumanHT12 beadchips.
(D) Lymphoblastic cells from three affected individuals and three asymptomatic spouses from Family A were treated overnight with
10 mg/ml emetin to inhibit nonsense-mediated decay (NMD). Total RNA was extracted with the QIAGEN RNeasy Mini kit (Invitrogen)
and reverse-transcribed with the SuperScript III First-Strand Kit (Invitrogen). RAD51 cDNA was amplified and sequenced with specific
primers located in exons 7 (Forward) and 10 (Reverse). Chromatograms for one affected individual and one spouse, showing lower levels
of mutated mRNA compared to WT mRNA in untreated cells and a comparable expression levels of both mRNA in cells pretreated with
emetin, are shown.
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Figure 3. Comparative Expression and Localization of RAD51
and DCC in Developing Mouse Cortex
(A) Quantification of RAD51 and DCC expression in mouse cere-
bral cortex sampled in quadruplicate at several stages of develop-
ment (E12, E15, E18, P1, P7, P15, 1 month, and 3 months) by
real-time PCR. Quantification of each sample was carried out
with the QIAGEN QuantiTect primer assays for DCC and RAD51.
PPIA and PGK1 were used as control genes. Each sample was run
in triplicate on a Lightcycler-1536 apparatus (Roche). Forty-five
two-step cycles (15 s at 95C and 30 s at 60C) were performed.
Analysis was performed with qbase Plus software (Biogazelle).
(B–G) Sagittal sections of the neocortex of E12 mouse embryos,
fixed overnight in paraformaldehyde 4%, and immunolabeled
with anti-RAD51 (1/50, sc-6862, Santa Cruz Biotechnology, Santa
Cruz, CA) (B–E) or anti-DCC (1/100, sc-6535, Santa Cruz) (F andG)
and counterstained with DAPI (C, E, G). Confocal plane (D, E).
Scale bar represents 220 mm (B, C, F, G) or 15 mm (D, E).
The Americaconsistent with this observation and reveal an unexpected
role of this gene in mammalian neurodevelopment.
To gain further insight into this function and to identify
a possible relationship between RAD51 and DCC, we
compared the expression of the two genes in the devel-
oping mouse cortex. DCC expression increased from
embryonic day 12 (E12) to embryonic day 15 (E15),
whereasRAD51 expressionwas strongest at E12; expression
of both genes declined thereafter (Figure 3A). The spatial
distribution of RAD51 was different from that of DCC
and evolved during brain development: at E12, RAD51
wasmostly detected in the cortical ventricular zone (prolif-
erative zone; Figures 3B and 3C), whereas DCC was present
in the preplate (postmitotic zone; Figures 3F and 3G),
confirming previous observations.16,17 In the cortex of
newborn mice (P0), RAD51 was mainly present in the
subplate (SP) and, in lesser amounts, in layer V (Figures
4A and 4B), whereas DCC was selectively located in axons
innervating the cortex (Figures 4C, 4D, 4G, and 4H). Strik-
ingly, RAD51was detected in a subpopulation of corticospi-
nal axons at the pyramidal decussation in 2-day-old (P2)
mice (Figures 4I and 4J), suggesting that RAD51 deficiency
could specifically alter the decussation process. RAD51 is
therefore specifically present in the developing mouse
cortex, in brain tissues and at stages that are critical for
the establishment of the corticospinal tract.
Interestingly, the subcellular location of RAD51 also
changed with the stage of development: RAD51 was
mostly detected in the nucleus of progenitor cells at E12
(Figures 3D and 3E) whereas it was mainly localized in
the cell soma in the subplate at P0 (Figures 4E and 4F)
and had a punctiform distribution at the pyramidal decus-
sation in P2 mice (Figures 4I0 and 4J0). These results suggest
that RAD51 could have several functions related to
different cellular localizations.
The precise mechanisms linking RAD51 deficiency to
MM are unclear, and the possible involvement of the
DNA repair function in MM pathogenesis remains to be
demonstrated. Insufficient RAD51-related DNA repair
during early corticogenesis might lead to excessive
apoptosis and altered central nervous system develop-
ment, as observed in mice lacking XRCC2, another gene
of the RAD51 family also involved in HR-mediated DNA
repair.18,19 The location of RAD51 in the cytoplasm of
cortical cells during mouse brain development, as previ-
ously described in other cell types, suggests, however,
a role of RAD51 different from its function in HR occurring
within the nucleus.20 It might have a direct or indirect role
in axonal guidance, as shown for DCC. In keeping with
this hypothesis, high RAD51 levels are associated with
increased expression of genes involved in actin remodeling
in nonneuronal cells.21 Nevertheless, the different cellular
locations of DCC and RAD51 during cortical development
suggest that these proteins do not interact directly.
Interestingly, homozygous Rad51/ rodent zygotes
show altered cell proliferation and abnormal cell
morphology and are unable to undergo embryonicn Journal of Human Genetics 90, 301–307, February 10, 2012 305
Figure 4. Comparative Localization of RAD51 and DCC in Mouse Brain at Postnatal Stages
(A–H) Cortical coronal section of a newborn (P0) mouse triple immunostained with anti-TBR1 (1/500, Millipore, Molsheim, France) to
label the subplate and layer VI, anti-CTIP2 (1/500, Abcam, Cambridge, UK) to label layer V, and either anti-RAD51 (1/50, sc-6862, Santa
Cruz) (A, B) or anti-DCC (1/100, sc-6535, Santa Cruz) (C, D), or immunolabeled only with anti-RAD51 (E, F) or anti-DCC (G, H) and
counterstained with DAPI (F, H).
(I and J) Coronal section of a P2 mouse at the pyramidal decussation, immunostained with anti-RAD51 (I, J) and anti-PKCg (1/100,
sc211, Santa-Cruz) to label the corticospinal tract (J).
(I0 and J0) Enlargements of (I) and (J); arrows point to the same area.
Scale bar represents 120 mm (A–D), 30 mm (E–H), 250 mm (I, J), or 100 mm (I0, J0).development after embryonic day 6.22,23 Heterozygous
Rad51þ/ mice are viable, fertile, and appear normal in
outer appearance, but neither the morphological organiza-
tion of their central nervous system nor their motor
phenotype has yet been investigated.22,23 Therefore, it is
currently unclear whether the Rad51þ/ mice reproduce,
at least in part, the human phenotype. Further character-
ization of mouse models is necessary to address this issue
and to unravel themechanisms by which RAD51mutation
leads to mirror movements in humans.
A striking feature is the reduced penetrance associated
with RAD51mutations: in Family A, 8 out of the 16 individ-
uals with the p.Arg254* mutation were asymptomatic
at examination, for a penetrance of 50%. The absence of
mirror movements in these individuals could be, for306 The American Journal of Human Genetics 90, 301–307, Februaryexample, due to a higher expression of RAD51 from
the remaining normal allele or to other genetic or
epigenetic modifiers. Interestingly, embryonic develop-
ment of Rad51/ mice progressed further in a p53-null
background, supporting the hypothesis that the genetic
background modulates the phenotype induced by the
RAD51mutation.23 So far,DCC andRAD51 seemto account
for most MM families: over the four families studied in
our laboratory, mutations in DCC were identified in one
family4 and mutations in RAD51 were identified in two
other families. One family (Family C) was negative for
both genes but the existence of intragenic microrearrange-
ments missed by sequencing was not tested and therefore
it is uncertain whether a third gene responsible for MM
exists.10, 2012
Study of MM subjects or models provide a unique
opportunity to investigate the network and mechanisms
underlying the bimanual motor control, which are, so far
largely unknown.2 Our findings therefore open a field of
investigation for researchers attempting to unravel the
molecular pathways underlying bimanual motor control
in humans.Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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